Smart use of off-patent medicines will be critical to rebuild healthcare systems successfully post-Covid

7 October 2021

Baton passes from Christoph Stoller to Rebecca Guntern as President of Medicines for Europe

1 October 2021

Rebecca Guntern (Sandoz) today begins an interim term as President […]

HERA must address outstanding weaknesses in EU pharma framework to be successful

16 September 2021

Medicines For Europe strongly supports the EU’s drive to learn from COVID-19 […]

EU must take the lead to ensure security of supply for medicines

16 June 2021

Legislative reforms aligned with current off-patent market conditions are the […]

Open borders that prioritise essential goods key to medicines supply in Europe

2 June 2021

EU Industrial strategy should be key to improving medicines supply chains

17 May 2021

The newly launched update of the industrial strategy aims to […]

“Off patent medicines essential for a fairer, healthier, and sustainable Europe” says President Christoph Stoller

30 April 2021

Christoph Stoller will speak at 3A CONFERENCE – Availability, Accessibility, […]

European patients need improved access to biosimilar medicines

22 April 2021

Fifteen years after the first global approval, biosimilar medicines systemically […]

New report assesses progress on biosimilar medicine policies across Europe

29 March 2021

Biosimilar medicines are increasingly relevant to public health as emphasised by the […]

A new medicines trade and health security agenda for the European Commission

19 February 2021

In response to the European Commission Trade Communication published on […]